Insmed Incorporated (INSM)
NASDAQ
Real-time Data
01:30 PM
Day's Range
101.6052 wk Range
90.39Overview - INSM - Insmed Incorporated
Key Statistics
Valuation
Enterprise Value
25.42B
P/E (Trailing)
‪-18.35‬
P/E (Forward)
‪154.37‬
PEG Ratio
‪0.19‬
Price / Sales (TTM)
‪22.71‬
Price / Book
‪34.10‬
EV / EBITDA
‪-31.98‬
Profitability
Gross Margin
‪84.20%‬
Profit Margin
‪-76.94%‬
Operating Margin
‪-23.80%‬
Return on Assets
‪-22.16%‬
Return on Equity
‪-87.21%‬
Ownership
Shares Outstanding
218.28M
Float
216.93M
Short % of Shares Outstanding
‪5.90%‬
Held by Insiders
‪0.50%‬
Held by Institutions
‪105.02%‬
Price stats
Beta
‪0.81‬
50-Day Avg
‪118.79‬
200-Day Avg
‪135.92‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
23 analysts
Average price target
‪$ 200.18‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - INSM - Insmed Incorporated
Peers - INSM - Insmed Incorporated
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- INSMNASDAQInsmed Incorporated25.73BMarket Cap-20.22%52-week change-18.35P/E (Trailing)‪-76.94%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - INSM - Insmed Incorporated
About
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
